# Atsufumi Kawabata

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 204 papers | 5,104 citations | 39 h-index | 59 g-index |
| 221 ext. papers | 5,704 ext. citations | 5.1 avg, IF | 5.56 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 204 | Development of hepatic impairment aggravates chemotherapy-induced peripheral neuropathy following oxaliplatin treatment: Evidence from clinical and preclinical studies.. *Journal of Pharmacological Sciences*, **2022**, 148, 315-325 | 3.7 | |
| 203 | Role of neuron-derived ATP in paclitaxel-induced HMGB1 release from macrophages and peripheral neuropathy.. *Journal of Pharmacological Sciences*, **2022**, 148, 156-161 | 3.7 | 0 |
| 202 | Effects of Bepridil and Pimozide, Existing Medicines Capable of Blocking T-Type Ca Channels, on Visceral Pain in Mice. *Biological and Pharmaceutical Bulletin*, **2021**, 44, 461-464 | 2.3 | 0 |
| 201 | Estrogen decline is a risk factor for paclitaxel-induced peripheral neuropathy: Clinical evidence supported by a preclinical study. *Journal of Pharmacological Sciences*, **2021**, 146, 49-57 | 3.7 | 5 |
| 200 | Macrophage as a Peripheral Pain Regulator. *Cells*, **2021**, 10, | 7.9 | 8 |
| 199 | Role of high-mobility group box 1 and its modulation by thrombomodulin/thrombin axis in neuropathic and inflammatory pain. *British Journal of Pharmacology*, **2021**, 178, 798-812 | 8.6 | 12 |
| 198 | Development of diabetes mellitus following hormone therapy in prostate cancer patients is associated with early progression to castration resistance. *Scientific Reports*, **2021**, 11, 17157 | 4.9 | |
| 197 | Caspase-Dependent HMGB1 Release from Macrophages Participates in Peripheral Neuropathy Caused by Bortezomib, a Proteasome-Inhibiting Chemotherapeutic Agent, in Mice. *Cells*, **2021**, 10, | 7.9 | 1 |
| 196 | Itch and pain caused by intradermal injection of sulfides in mouse cheek: Effect of genetic deletion of Cav3.2 T-type calcium channels. *Proceedings for Annual Meeting of the Japanese Pharmacological Society*, **2021**, 94, 3-P1-08 | 0 | |
| 195 | Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan.. *PLoS ONE*, **2021**, 16, e0261473 | 2.7 | 0 |
| 194 | HMGB1 and its membrane receptors as therapeutic targets in an intravesical substance P-induced bladder pain syndrome mouse model. *Journal of Pharmacological Sciences*, **2020**, 143, 112-116 | 3.7 | 3 |
| 193 | Tacrolimus, a calcineurin inhibitor, promotes capsaicin-induced colonic pain in mice. *Journal of Pharmacological Sciences*, **2020**, 143, 60-63 | 3.7 | |
| 192 | Middle molecular weight heparinylphenylalanine, an RAGE blocker, prevents oxaliplatin-induced peripheral neuropathy and butyrate-induced colonic pain in mice. *Proceedings for Annual Meeting of the Japanese Pharmacological Society*, **2020**, 93, 1-P-022 | 0 | |
| 191 | Role of HMGB1 in Chemotherapy-Induced Peripheral Neuropathy. *International Journal of Molecular Sciences*, **2020**, 22, | 6.3 | 7 |
| 190 | A Combination of Cryopreservation and Kneading Maintains the Usability of Mohs Paste. *Chemical and Pharmaceutical Bulletin*, **2020**, 68, 516-519 | 1.9 | |
| 189 | Changes in Percutaneous Absorption of Fentanyl Patches in Rats Treated with a Sebum-Like Secretion. *Chemical and Pharmaceutical Bulletin*, **2020**, 68, 879-884 | 1.9 | 0 |
| 188 | Essential role of Ca3.2 T-type calcium channels in butyrate-induced colonic pain and nociceptor hypersensitivity in mice. *European Journal of Pharmacology*, **2020**, 887, 173576 | 5.3 | 2 |

| | | | |
|---|---|---|---|
| 187 | Cystitis-Related Bladder Pain Involves ATP-Dependent HMGB1 Release from Macrophages and Its Downstream HS/Ca3.2 Signaling in Mice. *Cells*, **2020**, 9, | 7.9 | 15 |
| 186 | Ca3.2 overexpression in L4 dorsal root ganglion neurons after L5 spinal nerve cutting involves Egr-1, USP5 and HMGB1 in rats: An emerging signaling pathway for neuropathic pain. *European Journal of Pharmacology*, **2020**, 888, 173587 | 5.3 | 9 |
| 185 | Genetic deletion of Ca3.2 T-type calcium channels abolishes HS-dependent somatic and visceral pain signaling in C57BL/6 mice. *Journal of Pharmacological Sciences*, **2019**, 140, 310-312 | 3.7 | 7 |
| 184 | Prenylflavanones as Novel T-Type Calcium Channel Blockers Useful for Pain Therapy. *Natural Product Communications*, **2019**, 14, 1934578X1987344 | 0.9 | |
| 183 | Dietary ascorbic acid restriction in GNL/SMP30-knockout mice unveils the role of ascorbic acid in regulation of somatic and visceral pain sensitivity. *Biochemical and Biophysical Research Communications*, **2019**, 511, 705-710 | 3.4 | 1 |
| 182 | NNC 55-0396, a T-type calcium channel blocker, protects against the brain injury induced by middle cerebral artery occlusion and reperfusion in mice. *Journal of Pharmacological Sciences*, **2019**, 140, 193-196 | 3.7 | 2 |
| 181 | Role of non-macrophage cell-derived HMGB1 in oxaliplatin-induced peripheral neuropathy and its prevention by the thrombin/thrombomodulin system in rodents: negative impact of anticoagulants. *Journal of Neuroinflammation*, **2019**, 16, 199 | 10.1 | 27 |
| 180 | Regulation of Cav3.2-mediated pain signals by hydrogen sulfide. *Proceedings for Annual Meeting of the Japanese Pharmacological Society*, **2019**, 92, 2-S17-3 | 0 | |
| 179 | Role of macrophage derived HMGB1 as an algogenic molecule therapeutic target in visceral pain. *Pain Research*, **2019**, 34, 24-30 | 0 | |
| 178 | Evaluation of Transdermal Penetration in Fentanyl Tape Using Franz Diffusion Cells: Changes in Drug Release and Skin Permeation under the Hyperthermia. *Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)*, **2019**, 45, 416-422 | 0.1 | 1 |
| 177 | The C-Reactive Protein/Albumin Ratio Is Useful for Predicting Short-Term Survival in Cancer and Noncancer Patients. *Journal of Palliative Medicine*, **2019**, 22, 532-537 | 2.2 | 12 |
| 176 | Critical role of Ca3.2 T-type calcium channels in the peripheral neuropathy induced by bortezomib, a proteasome-inhibiting chemotherapeutic agent, in mice. *Toxicology*, **2019**, 413, 33-39 | 4.4 | 23 |
| 175 | Involvement of the cystathionine-lyase/Ca3.2 pathway in substance P-induced bladder pain in the mouse, a model for nonulcerative bladder pain syndrome. *Neuropharmacology*, **2018**, 133, 254-263 | 5.5 | 6 |
| 174 | Prostanoid-dependent bladder pain caused by proteinase-activated receptor-2 activation in mice: Involvement of TRPV1 and T-type Ca channels. *Journal of Pharmacological Sciences*, **2018**, 136, 46-49 | 3.7 | 3 |
| 173 | Role of Thrombin in Soluble Thrombomodulin-Induced Suppression of Peripheral HMGB1-Mediated Allodynia in Mice. *Journal of NeuroImmune Pharmacology*, **2018**, 13, 179-188 | 6.9 | 7 |
| 172 | Involvement of NF-B in the upregulation of cystathionine-lyase, a hydrogen sulfide-forming enzyme, and bladder pain accompanying cystitis in mice. *Clinical and Experimental Pharmacology and Physiology*, **2018**, 45, 355-361 | 3 | 5 |
| 171 | Involvement of Voltage-Gated Calcium Channels in Inflammation and Inflammatory Pain. *Biological and Pharmaceutical Bulletin*, **2018**, 41, 1127-1134 | 2.3 | 26 |
| 170 | Design and synthesis of novel anti-hyperalgesic agents based on 6-prenylnaringenin as the T-type calcium channel blockers. *Bioorganic and Medicinal Chemistry*, **2018**, 26, 4410-4427 | 3.4 | 7 |

| | | | |
|---|---|---|---|
| 169 | Blockade of T-type calcium channels by 6-prenylnaringenin, a hop component, alleviates neuropathic and visceral pain in mice. *Neuropharmacology*, **2018**, 138, 232-244 | 5.5 | 14 |
| 168 | Middle molecular weight heparinylphenylalanine is an analgesic with reduced risk of hemorrhage. *Proceedings for Annual Meeting of the Japanese Pharmacological Society*, **2018**, WCP2018, PO3-2-14 | 0 | |
| 167 | High mobility group box 1 suppresses smooth muscle tension in rat aorta via Toll-like receptor 4-dependent upregulation of iNOS. *Proceedings for Annual Meeting of the Japanese Pharmacological Society*, **2018**, WCP2018, PO4-2-28 | 0 | |
| 166 | Human soluble thrombomodulin-induced blockade of peripheral HMGB1-dependent allodynia in mice requires both the lectin-like and EGF-like domains. *Biochemical and Biophysical Research Communications*, **2018**, 495, 634-638 | 3.4 | 11 |
| 165 | Zinc deficiency promotes cystitis-related bladder pain by enhancing function and expression of Ca3.2 in mice. *Toxicology*, **2018**, 393, 102-112 | 4.4 | 13 |
| 164 | Paclitaxel-induced HMGB1 release from macrophages and its implication for peripheral neuropathy in mice: Evidence for a neuroimmune crosstalk. *Neuropharmacology*, **2018**, 141, 201-213 | 5.5 | 39 |
| 163 | High glucose induces N-linked glycosylation-mediated functional upregulation and overexpression of Ca3.2 T-type calcium channels in neuroendocrine-like differentiated human prostate cancer cells. *Journal of Pharmacological Sciences*, **2017**, 133, 57-60 | 3.7 | 6 |
| 162 | Enhanced Hyperthermic Responses to Lipopolysaccharide in Mice Exposed to Repeated Cold Stress. *Pharmacology*, **2017**, 99, 172-178 | 2.3 | 1 |
| 161 | Repeated Cold Stress Reduces Cyclophosphamide-Induced Cystitis/Bladder Pain and Macrophage Activity in Mice. *Pharmacology*, **2017**, 99, 286-290 | 2.3 | 1 |
| 160 | Hydrogen Sulfide and T-Type Ca2+ Channels in Pain Processing, Neuronal Differentiation and Neuroendocrine Secretion. *Pharmacology*, **2017**, 99, 196-203 | 2.3 | 17 |
| 159 | Tacrolimus Triggers Transient Receptor Potential Vanilloid-1-Dependent Relapse of Pancreatitis-Related Pain in Mice. *Pharmacology*, **2017**, 99, 281-285 | 2.3 | 4 |
| 158 | Macrophage-derived HMGB1 as a Pain Mediator in the Early Stage of Acute Pancreatitis in Mice: Targeting RAGE and CXCL12/CXCR4 Axis. *Journal of NeuroImmune Pharmacology*, **2017**, 12, 693-707 | 6.9 | 29 |
| 157 | Repeated Cold Stress Enhances the Acute Restraint Stress-Induced Hyperthermia in Mice. *Biological and Pharmaceutical Bulletin*, **2017**, 40, 11-16 | 2.3 | 10 |
| 156 | Endogenous Hydrogen Sulfide Enhances Cell Proliferation of Human Gastric Cancer AGS Cells. *Biological and Pharmaceutical Bulletin*, **2016**, 39, 887-90 | 2.3 | 21 |
| 155 | Selective sensitization of C-fiber nociceptors by hydrogen sulfide. *Journal of Pharmacological Sciences*, **2016**, 130, 38-41 | 3.7 | 1 |
| 154 | The prostaglandin E2/EP4 receptor/cyclic AMP/T-type Ca(2+) channel pathway mediates neuritogenesis in sensory neuron-like ND7/23 cells. *Journal of Pharmacological Sciences*, **2016**, 130, 177-80 | 3.7 | 13 |
| 153 | Peripheral HMGB1-induced hyperalgesia in mice: Redox state-dependent distinct roles of RAGE and TLR4. *Journal of Pharmacological Sciences*, **2016**, 130, 139-42 | 3.7 | 33 |
| 152 | Therapeutic potential of RQ-00311651, a novel T-type Ca2+ channel blocker, in distinct rodent models for neuropathic and visceral pain. *Pain*, **2016**, 157, 1655-1665 | 8 | 26 |

| | | | |
|---|---|---|---|
| 151 | Involvement of high mobility group box 1 in the development and maintenance of chemotherapy-induced peripheral neuropathy in rats. *Toxicology*, **2016**, 365, 48-58 | 4.4 | 29 |
| 150 | H2S and Pain: A Novel Aspect for Processing of Somatic, Visceral and Neuropathic Pain Signals. *Handbook of Experimental Pharmacology*, **2015**, 230, 217-30 | 3.2 | 14 |
| 149 | Hydrogen sulfide and neuronal differentiation: focus on Ca2+ channels. *Nitric Oxide - Biology and Chemistry*, **2015**, 46, 50-4 | 5 | 14 |
| 148 | Functional upregulation of the H2S/Cav3.2 channel pathway accelerates secretory function in neuroendocrine-differentiated human prostate cancer cells. *Biochemical Pharmacology*, **2015**, 97, 300-9 | 6 | 20 |
| 147 | Roles of Cav3.2 and TRPA1 channels targeted by hydrogen sulfide in pancreatic nociceptive processing in mice with or without acute pancreatitis. *Journal of Neuroscience Research*, **2015**, 93, 361-9 | 4.4 | 22 |
| 146 | Intravenous Administration of Cilostazol Nanoparticles Ameliorates Acute Ischemic Stroke in a Cerebral Ischemia/Reperfusion-Induced Injury Model. *International Journal of Molecular Sciences*, **2015**, 16, 29329-44 | 6.3 | 29 |
| 145 | Mechanisms for proteinase-activated receptor 1-triggered prostaglandin E2 generation in mouse osteoblastic MC3T3-E1 cells. *Biological Chemistry*, **2015**, 396, 153-62 | 4.5 | 7 |
| 144 | Polaprezinc attenuates cyclophosphamide-induced cystitis and related bladder pain in mice. *Journal of Pharmacological Sciences*, **2015**, 127, 223-8 | 3.7 | 16 |
| 143 | Ouabain exerts cytoprotection by diminishing the intracellular K(+) concentration increase caused by distinct stimuli in human leukemic cells. *Journal of Pharmacy and Pharmacology*, **2015**, 67, 126-32 | 4.8 | 1 |
| 142 | Bladder pain relief by HMGB1 neutralization and soluble thrombomodulin in mice with cyclophosphamide-induced cystitis. *Neuropharmacology*, **2014**, 79, 112-8 | 5.5 | 36 |
| 141 | Endogenous and exogenous hydrogen sulfide facilitates T-type calcium channel currents in Cav3.2-expressing HEK293 cells. *Biochemical and Biophysical Research Communications*, **2014**, 445, 225-9 | 3.4 | 47 |
| 140 | Recombinant human soluble thrombomodulin prevents peripheral HMGB1-dependent hyperalgesia in rats. *British Journal of Pharmacology*, **2013**, 170, 1233-41 | 8.6 | 28 |
| 139 | AKAP-dependent sensitization of Ca(v) 3.2 channels via the EP(4) receptor/cAMP pathway mediates PGE(2) -induced mechanical hyperalgesia. *British Journal of Pharmacology*, **2013**, 168, 734-45 | 8.6 | 24 |
| 138 | T-type calcium channels: functional regulation and implication in pain signaling. *Journal of Pharmacological Sciences*, **2013**, 122, 244-50 | 3.7 | 49 |
| 137 | Inhibition by hydrogen sulfide of rabbit platelet aggregation and calcium mobilization. *Biological and Pharmaceutical Bulletin*, **2013**, 36, 1278-82 | 2.3 | 18 |
| 136 | Antihyperalgesic effect of buprenorphine involves nociceptin/orphanin FQ peptide-receptor activation in rats with spinal nerve injury-induced neuropathy. *Journal of Pharmacological Sciences*, **2013**, 122, 51-4 | 3.7 | 9 |
| 135 | Contribution of TRPA1 as a downstream signal of proteinase-activated receptor-2 to pancreatic pain. *Journal of Pharmacological Sciences*, **2013**, 123, 284-7 | 3.7 | 17 |
| 134 | Colonic hydrogen sulfide-induced visceral pain and referred hyperalgesia involve activation of both Ca(v)3.2 and TRPA1 channels in mice. *Journal of Pharmacological Sciences*, **2012**, 119, 293-6 | 3.7 | 35 |

| | | | |
|---|---|---|---|
| 133 | Involvement of the endogenous hydrogen sulfide/Ca(v) 3.2 T-type Ca2+ channel pathway in cystitis-related bladder pain in mice. *British Journal of Pharmacology*, **2012**, 167, 917-28 | 8.6 | 48 |
| 132 | Topical application of disodium isostearyl 2-O-L-ascorbyl phosphate, an amphiphilic ascorbic acid derivative, reduces neuropathic hyperalgesia in rats. *British Journal of Pharmacology*, **2012**, 166, 1058-68 | 8.6 | 11 |
| 131 | Hydrogen sulfide-induced mechanical hyperalgesia and allodynia require activation of both Cav3.2 and TRPA1 channels in mice. *British Journal of Pharmacology*, **2012**, 166, 1738-43 | 8.6 | 66 |
| 130 | Roles of the Hydrogen Sulfide/T-Type Calcium Channel System in Somatic and Visceral Pain Processing. *Frontiers of Gastrointestinal Research*, **2012**, 212-218 | | |
| 129 | Involvement of ERK in NMDA receptor-independent cortical neurotoxicity of hydrogen sulfide. *Biochemical and Biophysical Research Communications*, **2011**, 414, 727-32 | 3.4 | 19 |
| 128 | Chelating luminal zinc mimics hydrogen sulfide-evoked colonic pain in mice: possible involvement of T-type calcium channels. *Neuroscience*, **2011**, 181, 257-64 | 3.9 | 50 |
| 127 | Prostaglandin E2 and pain--an update. *Biological and Pharmaceutical Bulletin*, **2011**, 34, 1170-3 | 2.3 | 208 |
| 126 | Lipid mediators and pain signaling. Foreword. *Biological and Pharmaceutical Bulletin*, **2011**, 34, 1153 | 2.3 | 3 |
| 125 | ONO-8130, a selective prostanoid EP1 receptor antagonist, relieves bladder pain in mice with cyclophosphamide-induced cystitis. *Pain*, **2011**, 152, 1373-1381 | 8 | 42 |
| 124 | Delayed production of arachidonic acid contributes to the delay of proteinase-activated receptor-1 (PAR1)-triggered prostaglandin E2 release in rat gastric epithelial RGM1 cells. *Journal of Cellular Biochemistry*, **2011**, 112, 909-15 | 4.7 | 4 |
| 123 | Involvement of Src kinase in T-type calcium channel-dependent neuronal differentiation of NG108-15 cells by hydrogen sulfide. *Journal of Neurochemistry*, **2010**, 114, 512-9 | 6 | 22 |
| 122 | The proteinase/proteinase-activated receptor-2/transient receptor potential vanilloid-1 cascade impacts pancreatic pain in mice. *Life Sciences*, **2010**, 87, 643-50 | 6.8 | 15 |
| 121 | Curcumin Inhibits the proteinase-activated receptor-2-triggered prostaglandin E2 production by suppressing cyclooxygenase-2 upregulation and Akt-dependent activation of nuclear factor-Β in human lung epithelial cells. *Journal of Pharmacological Sciences*, **2010**, 114, 225-9 | 3.7 | 21 |
| 120 | Upregulation of Ca(v)3.2 T-type calcium channels targeted by endogenous hydrogen sulfide contributes to maintenance of neuropathic pain. *Pain*, **2010**, 150, 183-191 | 8 | 94 |
| 119 | Phosphorylation of ERK in the spinal dorsal horn following pancreatic pronociceptive stimuli with proteinase-activated receptor-2 agonists and hydrogen sulfide in rats: evidence for involvement of distinct mechanisms. *Journal of Neuroscience Research*, **2010**, 88, 3198-205 | 4.4 | 18 |
| 118 | Opposite effects of two thiazolidinediones, ciglitazone and troglitazone, on proteinase-activated receptor-1-triggered prostaglandin E(2) release. *Toxicology*, **2010**, 268, 40-5 | 4.4 | 1 |
| 117 | Hydrogen sulfide evokes neurite outgrowth and expression of high-voltage-activated Ca2+ currents in NG108-15 cells: involvement of T-type Ca2+ channels. *Journal of Neurochemistry*, **2009**, 108, 676-84 | 6 | 34 |
| 116 | Rhodanese, but not cystathionine-gamma-lyase, is associated with dextran sulfate sodium-evoked colitis in mice: a sign of impaired colonic sulfide detoxification?. *Toxicology*, **2009**, 264, 96-103 | 4.4 | 23 |

| | | | |
|---|---|---|---|
| 115 | Hyperalgesia induced by spinal and peripheral hydrogen sulfide: evidence for involvement of Cav3.2 T-type calcium channels. *Pain*, **2009**, 142, 127-32 | 8 | 106 |
| 114 | Proteinase-activated receptor-2-triggered prostaglandin E(2) release, but not cyclooxygenase-2 upregulation, requires activation of the phosphatidylinositol 3-kinase/Akt / nuclear factor-kappaB pathway in human alveolar epithelial cells. *Journal of Pharmacological Sciences*, **2009**, 111, 269-75 | 3.7 | 17 |
| 113 | Gastrointestinal roles for proteinase-activated receptors in health and disease. *British Journal of Pharmacology*, **2008**, 153 Suppl 1, S230-40 | 8.6 | 62 |
| 112 | Signal transduction for formation/release of interleukin-8 caused by a PAR2-activating peptide in human lung epithelial cells. *Regulatory Peptides*, **2008**, 145, 42-8 | | 15 |
| 111 | PAR2 triggers IL-8 release via MEK/ERK and PI3-kinase/Akt pathways in GI epithelial cells. *Biochemical and Biophysical Research Communications*, **2008**, 377, 622-626 | 3.4 | 41 |
| 110 | Basic and translational research on proteinase-activated receptors: preface. *Journal of Pharmacological Sciences*, **2008**, 108, 406-7 | 3.7 | 2 |
| 109 | Evidence that PAR2-triggered prostaglandin E2 (PGE2) formation involves the ERK-cytosolic phospholipase A2-COX-1-microsomal PGE synthase-1 cascade in human lung epithelial cells. *Cell Biochemistry and Function*, **2008**, 26, 279-82 | 4.2 | 14 |
| 108 | Direct inhibition of endothelial nitric oxide synthase by hydrogen sulfide: contribution to dual modulation of vascular tension. *Toxicology*, **2007**, 232, 138-46 | 4.4 | 155 |
| 107 | Hydrogen sulfide inhibits activity of three isoforms of recombinant nitric oxide synthase. *Toxicology* , **2007**, 241, 92-7 | 4.4 | 88 |
| 106 | Mechanisms for prostaglandin E2 formation caused by proteinase-activated receptor-1 activation in rat gastric mucosal epithelial cells. *Biochemical Pharmacology*, **2007**, 73, 103-14 | 6 | 18 |
| 105 | Dual modulation of the tension of isolated gastric artery and gastric mucosal circulation by hydrogen sulfide in rats. *Inflammopharmacology*, **2007**, 15, 288-92 | 5.1 | 33 |
| 104 | Proteinase-activated receptors in the gastrointestinal system: a functional linkage to prostanoids. *Inflammopharmacology*, **2007**, 15, 246-51 | 5.1 | 16 |
| 103 | A protective role of hydrogen sulfide against oxidative stress in rat gastric mucosal epithelium. *Toxicology*, **2007**, 241, 11-8 | 4.4 | 96 |
| 102 | Hydrogen sulfide causes relaxation in mouse bronchial smooth muscle. *Journal of Pharmacological Sciences*, **2007**, 104, 392-6 | 3.7 | 57 |
| 101 | Hydrogen sulfide as a novel nociceptive messenger. *Pain*, **2007**, 132, 74-81 | 8 | 137 |
| 100 | Roles for H2S in pain processing: Response to Cunha and Verri. *Pain*, **2007**, 130, 302-303 | 8 | |
| 99 | The proteinase inhibitor camostat mesilate suppresses pancreatic pain in rodents. *Life Sciences*, **2007**, 80, 1999-2004 | 6.8 | 22 |
| 98 | Colonic hyperalgesia triggered by proteinase-activated receptor-2 in mice: involvement of endogenous bradykinin. *Neuroscience Letters*, **2006**, 402, 167-72 | 3.3 | 24 |

| | | | |
|---|---|---|---|
| 97 | Mechanisms for modulation of mouse gastrointestinal motility by proteinase-activated receptor (PAR)-1 and -2 in vitro. *Life Sciences*, **2006**, 78, 950-7 | 6.8 | 17 |
| 96 | Antiallodynic effect of etidronate, a bisphosphonate, in rats with adjuvant-induced arthritis: involvement of ATP-sensitive K+ channels. *Neuropharmacology*, **2006**, 51, 182-90 | 5.5 | 16 |
| 95 | Suppression of pancreatitis-related allodynia/hyperalgesia by proteinase-activated receptor-2 in mice. *British Journal of Pharmacology*, **2006**, 148, 54-60 | 8.6 | 40 |
| 94 | Distinct activity of peptide mimetic intracellular ligands (pepducins) for proteinase-activated receptor-1 in multiple cells/tissues. *Annals of the New York Academy of Sciences*, **2006**, 1091, 445-59 | 6.5 | 27 |
| 93 | Signal transduction for proteinase-activated receptor-2-triggered prostaglandin E2 formation in human lung epithelial cells. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 315, 576-89 | 4.7 | 44 |
| 92 | Physiology and pathophysiology of proteinase-activated receptors (PARs): PARs in the respiratory system: cellular signaling and physiological/pathological roles. *Journal of Pharmacological Sciences*, **2005**, 97, 20-4 | 3.7 | 51 |
| 91 | Physiology and pathophysiology of proteinase-activated receptors (PARs): PAR-2 as a potential therapeutic target. *Journal of Pharmacological Sciences*, **2005**, 97, 38-42 | 3.7 | 32 |
| 90 | 2-Furoyl-LIGRL-NH2, a potent agonist for proteinase-activated receptor-2, as a gastric mucosal cytoprotective agent in mice. *British Journal of Pharmacology*, **2005**, 144, 212-9 | 8.6 | 25 |
| 89 | Binding of a highly potent protease-activated receptor-2 (PAR2) activating peptide, [3H]2-furoyl-LIGRL-NH2, to human PAR2. *British Journal of Pharmacology*, **2005**, 145, 255-63 | 8.6 | 24 |
| 88 | Potent and metabolically stable agonists for protease-activated receptor-2: evaluation of activity in multiple assay systems in vitro and in vivo. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 309, 1098-107 | 4.7 | 62 |
| 87 | Proteinase-activated receptor-2-mediated relaxation in mouse tracheal and bronchial smooth muscle: signal transduction mechanisms and distinct agonist sensitivity. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 311, 402-10 | 4.7 | 34 |
| 86 | Distinct roles for protease-activated receptors 1 and 2 in vasomotor modulation in rat superior mesenteric artery. *Cardiovascular Research*, **2004**, 61, 683-92 | 9.9 | 23 |
| 85 | A protective role of protease-activated receptor 1 in rat gastric mucosa. *Gastroenterology*, **2004**, 126, 208-19 | 13.3 | 38 |
| 84 | The potent inducible nitric oxide synthase inhibitor ONO-1714 inhibits neuronal NOS and exerts antinociception in rats. *Neuroscience Letters*, **2004**, 365, 111-5 | 3.3 | 19 |
| 83 | Receptor-activating peptides for PAR-1 and PAR-2 relax rat gastric artery via multiple mechanisms. *Life Sciences*, **2004**, 75, 2689-702 | 6.8 | 12 |
| 82 | Activation of trigeminal nociceptive neurons by parotid PAR-2 activation in rats. *NeuroReport*, **2004**, 15, 1617-21 | 1.7 | 14 |
| 81 | Impact of a pharmacist-implemented anemia management in outpatients with end-stage renal disease in Japan. *Biological and Pharmaceutical Bulletin*, **2004**, 27, 1831-3 | 2.3 | 19 |
| 80 | Modulation of capsaicin-evoked visceral pain and referred hyperalgesia by protease-activated receptors 1 and 2. *Journal of Pharmacological Sciences*, **2004**, 94, 277-85 | 3.7 | 52 |

| | | | |
|---|---|---|---|
| 79 | Protease-Activated Receptors (PARs) as Therapeutic Targets: Development of Agonists / Antagonists and Modulation of Gastrointestinal Functions. *Drug Design Reviews Online*, **2004**, 1, 287-296 | | 5 |
| 78 | Modulation of gastric function by proteinase-activated receptors. *Drug Development Research*, **2003**, 60, 9-13 | 5.1 | 5 |
| 77 | Involvement of EDHF in the hypotension and increased gastric mucosal blood flow caused by PAR-2 activation in rats. *British Journal of Pharmacology*, **2003**, 140, 247-54 | 8.6 | 20 |
| 76 | Gastrointestinal functions of proteinase-activated receptors. *Life Sciences*, **2003**, 74, 247-54 | 6.8 | 53 |
| 75 | Effect of a potent iNOS inhibitor (ONO-1714) on acetaminophen-induced hepatotoxicity in the rat. *Life Sciences*, **2003**, 74, 793-802 | 6.8 | 28 |
| 74 | The PAR-1-activating peptide facilitates pepsinogen secretion in rats. *Peptides*, **2003**, 24, 1449-51 | 3.8 | 9 |
| 73 | Gastrointestinal functions of proteinase-activated receptors. *Life Sciences*, **2003**, 74, 247-247 | 6.8 | |
| 72 | Suppression by protease-activated receptor-2 activation of gastric acid secretion in rats. *European Journal of Pharmacology*, **2002**, 447, 87-90 | 5.3 | 29 |
| 71 | Effects of somatosensory cortical stimulation on expression of c-Fos in rat medullary dorsal horn in response to formalin-induced noxious stimulation. *Journal of Neuroscience Research*, **2002**, 68, 479-88 | 4.4 | 19 |
| 70 | Capsazepine partially inhibits neurally mediated gastric mucus secretion following activation of protease-activated receptor 2. *Clinical and Experimental Pharmacology and Physiology*, **2002**, 29, 360-1 | 3 | 23 |
| 69 | Protease-activated receptor-2 (PAR-2) in the rat gastric mucosa: immunolocalization and facilitation of pepsin/pepsinogen secretion. *British Journal of Pharmacology*, **2002**, 135, 1292-6 | 8.6 | 41 |
| 68 | Multiple roles for protease-activated receptor-2 in gastric mucosa. *Inflammopharmacology*, **2002**, 10, 343-349 | 5.1 | 2 |
| 67 | PAR-2: structure, function and relevance to human diseases of the gastric mucosa. *Expert Reviews in Molecular Medicine*, **2002**, 4, 1-17 | 6.7 | 31 |
| 66 | Capsazepine inhibits thermal hyperalgesia but not nociception triggered by protease-activated receptor-2 in rats. *The Japanese Journal of Pharmacology*, **2002**, 89, 184-7 | | 24 |
| 65 | Specific expression of spinal Fos after PAR-2 stimulation in mast cell-depleted rats. *NeuroReport*, **2002**, 13, 511-4 | 1.7 | 19 |
| 64 | Protease-activated receptor-2 (PAR-2) in the pancreas and parotid gland: Immunolocalization and involvement of nitric oxide in the evoked amylase secretion. *Life Sciences*, **2002**, 71, 2435-46 | 6.8 | 56 |
| 63 | The PAR-1-activating peptide attenuates carrageenan-induced hyperalgesia in rats. *Peptides*, **2002**, 23, 1181-3 | 3.8 | 33 |
| 62 | Role of N-methyl-D-aspartate receptors and the nitric oxide pathway in nociception/hyperalgesia elicited by protease-activated receptor-2 activation in mice and rats. *Neuroscience Letters*, **2002**, 329, 349-53 | 3.3 | 21 |

| | | | |
|---|---|---|---|
| 61 | Protease-activated receptor- 2 (PAR-2) : ???,????????????????. *Japanese Journal of Thrombosis and Hemostasis*, **2002**, 13, 467-476 | 0 | 0 |
| 60 | Lipopolysaccharide-induced subsensitivity of protease-activated receptor-2 in the mouse salivary glands in vivo. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2001**, 364, 281-4 | 3.4 | 12 |
| 59 | In vivo evidence that protease-activated receptors 1 and 2 modulate gastrointestinal transit in the mouse. *British Journal of Pharmacology*, **2001**, 133, 1213-8 | 8.6 | 58 |
| 58 | Secondary somatosensory cortex stimulation facilitates the antinociceptive effect of the NO synthase inhibitor through suppression of spinal nociceptive neurons in the rat. *Brain Research*, **2001**, 903, 110-6 | 3.7 | 18 |
| 57 | Factor Xa-evoked relaxation in rat aorta: involvement of PAR-2. *Biochemical and Biophysical Research Communications*, **2001**, 282, 432-5 | 3.4 | 45 |
| 56 | Ex vivo evidence that the phosphodiesterase inhibitor IBMX attenuates the up-regulation of PAR-2 in the endotoxemic rat aorta. *Thrombosis Research*, **2001**, 101, 513-5 | 8.2 | 6 |
| 55 | Specific distribution of sialic acids in animal tissues as examined by LC-ESI-MS after derivatization with 1,2-diamino-4,5-methylenedioxybenzene. *Analytical Chemistry*, **2001**, 73, 5422-8 | 7.8 | 48 |
| 54 | Peripheral PAR-2 triggers thermal hyperalgesia and nociceptive responses in rats. *NeuroReport*, **2001**, 12, 715-9 | 1.7 | 84 |
| 53 | The protease-activated receptor-2 agonist induces gastric mucus secretion and mucosal cytoprotection. *Journal of Clinical Investigation*, **2001**, 107, 1443-50 | 15.9 | 123 |
| 52 | Determination of mucin in salivary glands using sialic acids as the marker by high-performance liquid chromatography with fluorometric detection. *Analytical Biochemistry*, **2000**, 283, 119-21 | 3.1 | 13 |
| 51 | Fluorometric determination of mucin-type glycoproteins by the galactose oxidase-peroxidase method. *Analytical Biochemistry*, **2000**, 284, 87-92 | 3.1 | 9 |
| 50 | Proteinase-activated receptor-2 (PAR-2): regulation of salivary and pancreatic exocrine secretion in vivo in rats and mice. *British Journal of Pharmacology*, **2000**, 129, 1808-14 | 8.6 | 72 |
| 49 | Dual modulation by thrombin of the motility of rat oesophageal muscularis mucosae via two distinct protease-activated receptors (PARs): a novel role for PAR-4 as opposed to PAR-1. *British Journal of Pharmacology*, **2000**, 131, 578-84 | 8.6 | 28 |
| 48 | Roles of urokinase type plasminogen activator in a brain stab wound. *Brain Research*, **2000**, 887, 187-90 | 3.7 | 19 |
| 47 | Activation of protease-activated receptor-2 (PAR-2) triggers mucin secretion in the rat sublingual gland. *Biochemical and Biophysical Research Communications*, **2000**, 270, 298-302 | 3.4 | 56 |
| 46 | Somatosensory cortex stimulation-evoked analgesia in rats: potentiation by NO synthase inhibition. *Life Sciences*, **2000**, 66, PL271-6 | 6.8 | 20 |
| 45 | Characterization of the protease-activated receptor-1-mediated contraction and relaxation in the rat duodenal smooth muscle. *Life Sciences*, **2000**, 67, 2521-30 | 6.8 | 26 |
| 44 | Protease-activated receptor (PAR), a novel family of G protein-coupled seven trans-membrane domain receptors: activation mechanisms and physiological roles. *The Japanese Journal of Pharmacology*, **2000**, 82, 171-4 | | 60 |

| | | | |
|---|---|---|---|
| 43 | Characterization of protease-activated receptors in rat peritoneal mast cells. *The Japanese Journal of Pharmacology*, **2000**, 82, 74-7 | | 23 |
| 42 | Activation of protease-activated receptor-2 triggers salivation. *The Japanese Journal of Pharmacology*, **1999**, 79, 92 | | 2 |
| 41 | Enhancement of vascular permeability by specific activation of protease-activated receptor-1 in rat hindpaw: a protective role of endogenous and exogenous nitric oxide. *British Journal of Pharmacology*, **1999**, 126, 1856-62 | 8.6 | 35 |
| 40 | Modulation by protease-activated receptors of the rat duodenal motility in vitro: possible mechanisms underlying the evoked contraction and relaxation. *British Journal of Pharmacology*, **1999**, 128, 865-72 | 8.6 | 57 |
| 39 | Proteinase activated receptor 2: Role of extracellular loop 2 for ligand-mediated activation. *British Journal of Pharmacology*, **1999**, 128, 1105-13 | 8.6 | 45 |
| 38 | Increased vascular permeability by a specific agonist of protease-activated receptor-2 in rat hindpaw. *British Journal of Pharmacology*, **1998**, 125, 419-22 | 8.6 | 101 |
| 37 | Penetration of cisplatin into mouse brain by lipopolysaccharide. *Toxicology*, **1998**, 130, 107-13 | 4.4 | 39 |
| 36 | Roles of nitric oxide and prostaglandins in the increased permeability of the blood-brain barrier caused by lipopolysaccharide. *Environmental Toxicology and Pharmacology*, **1998**, 5, 35-41 | 5.8 | 34 |
| 35 | Cross tolerance to environmental stress and endotoxin. *Life Sciences*, **1998**, 62, PL 327-33 | 6.8 | 2 |
| 34 | Evidence that endogenous nitric oxide modulates plasma fibrinogen levels in the rat. *British Journal of Pharmacology*, **1996**, 117, 236-7 | 8.6 | 19 |
| 33 | Attenuation by prolonged nitric oxide synthase inhibition of the enhancement of fibrinolysis caused by environmental stress in the rat. *British Journal of Pharmacology*, **1996**, 119, 346-50 | 8.6 | 17 |
| 32 | 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one reverses the inhibition by sodium nitroprusside of thrombin-induced platelet aggregation in the rat. *Thrombosis Research*, **1996**, 82, 543-5 | 8.2 | 0 |
| 31 | Kyotorphin synthetase activity in rat adrenal glands and spinal cord. *Peptides*, **1996**, 17, 407-11 | 3.8 | 7 |
| 30 | Central antinociceptive effect of L-ornithine, a metabolite of L-arginine, in rats and mice. *European Journal of Pharmacology*, **1996**, 296, 23-31 | 5.3 | 10 |
| 29 | Lipopolysaccharide-induced platinum accumulation in the cerebral cortex after cisplatin administration in mice: Involvement of free radicals. *Environmental Toxicology and Pharmacology*, **1996**, 2, 321-6 | 5.8 | 12 |
| 28 | NG-nitro-L-arginine methyl ester and alpha-methyl-L-ornithine inhibit kyotorphin synthetase from rat brain. *Peptides*, **1995**, 16, 1317-9 | 3.8 | 5 |
| 27 | Effect of topical administration of L-arginine on formalin-induced nociception in the mouse: a dual role of peripherally formed NO in pain modulation. *British Journal of Pharmacology*, **1994**, 112, 547-50 | 8.6 | 119 |
| 26 | Comparison of antinociception induced by supraspinally administered L-arginine and kyotorphin. *British Journal of Pharmacology*, **1994**, 112, 817-22 | 8.6 | 14 |

| | | | |
|---|---|---|---|
| 25 | The noradrenaline precursor L-threo-3,4-dihydroxyphenylserine exhibits antinociceptive activity via central alpha-adrenoceptors in the mouse. *British Journal of Pharmacology*, **1994**, 111, 503-8 | 8.6 | 12 |
| 24 | L-Tyrosine-induced antinociception in the mouse: involvement of central delta-opioid receptors and bulbo-spinal noradrenergic system. *European Journal of Pharmacology*, **1993**, 233, 255-60 | 5.3 | 7 |
| 23 | L-arginine exerts a dual role in nociceptive processing in the brain: involvement of the kyotorphin-Met-enkephalin pathway and NO-cyclic GMP pathway. *British Journal of Pharmacology*, **1993**, 109, 73-9 | 8.6 | 93 |
| 22 | Characterization of platelet hypofunctions in rats under SART stress (repeated cold stress). *Thrombosis Research*, **1993**, 69, 197-207 | 8.2 | 9 |
| 21 | Possible involvement of oxygen-derived free radicals in abnormal hemostasis induced by SART stress (repeated cold stress) in laboratory animals. *Thrombosis Research*, **1993**, 72, 321-31 | 8.2 | 8 |
| 20 | L-leucyl-L-arginine, naltrindole and D-arginine block antinociception elicited by L-arginine in mice with carrageenin-induced hyperalgesia. *British Journal of Pharmacology*, **1992**, 107, 1096-101 | 8.6 | 57 |
| 19 | Antinociceptive effect of L-arginine on the carrageenin-induced hyperalgesia of the rat: possible involvement of central opioidergic systems. *European Journal of Pharmacology*, **1992**, 218, 153-8 | 5.3 | 61 |
| 18 | Changes in CNS levels of serotonin and its metabolite in SART-stressed (repeatedly cold-stressed) rats. *The Japanese Journal of Pharmacology*, **1991**, 56, 101-4 | | 24 |
| 17 | Blood coagulation and fibrinolysis in SART-stressed (repeated cold-stressed) rats and drug effects on the altered hemostatic parameters. *The Japanese Journal of Pharmacology*, **1991**, 56, 403-12 | | 9 |
| 16 | Blood Coagulation and Fibrinolysis in SART-Stressed (Repeated Cold-Stressed) Rats and Drug Effects on the Altered Hemostatic Parameters. *The Japanese Journal of Pharmacology*, **1991**, 56, 403-412 | | |
| 15 | Changes in CNS Levels of Serotonin and Its Metabolite in SART-Stressed (Repeatedly Cold-Stressed) Rats. *The Japanese Journal of Pharmacology*, **1991**, 56, 101-104 | | 7 |
| 14 | Subsensitivity to substance P in SART-stressed mice. *The Japanese Journal of Pharmacology*, **1989**, 49, 293-6 | | 2 |
| 13 | A characteristic pattern of active avoidance behavior in SART-stressed rats. *The Japanese Journal of Pharmacology*, **1989**, 49, 436-40 | | 3 |
| 12 | Impairment of passive avoidance performance in SART-stressed mice and the action of drugs. *The Japanese Journal of Pharmacology*, **1989**, 49, 111-7 | | 14 |
| 11 | A Characteristic Pattern of Active Avoidance Behavior in SART-Stressed Rats. *The Japanese Journal of Pharmacology*, **1989**, 49, 436-440 | | 1 |
| 10 | Impairment of Passive Avoidance Performance in SART-Stressed Mice and the Action of Drugs. *The Japanese Journal of Pharmacology*, **1989**, 49, 111-117 | | 2 |
| 9 | Changes in platelet count and related parameters in SART-stressed mice and the action of administered neurotropin. *The Japanese Journal of Pharmacology*, **1988**, 47, 349-56 | | 13 |
| 8 | Mechanism of the analgesic effect of neurotropin. *The Japanese Journal of Pharmacology*, **1988**, 48, 165-73 | | 26 |

| | | |
|---|---|---|
| 7 | The abnormal open-field behavior of SART-stressed rats and effects of some drugs on it. *The Japanese Journal of Pharmacology*, **1988**, 48, 479-90 | 25 |
| 6 | Changes in Platelet Count and Related Parameters in SART-Stressed Mice and the Action of Administered Neurotropin. *The Japanese Journal of Pharmacology*, **1988**, 47, 349-356 | |
| 5 | Electrocorticogram in rats loaded with SART stress (repeated cold stress). *The Japanese Journal of Pharmacology*, **1987**, 45, 365-72 | 15 |
| 4 | Electrocorticogram in Rats Loaded with SART Stress (Repeated Cold Stress). *The Japanese Journal of Pharmacology*, **1987**, 45, 365-372 | 1 |
| 3 | Effects of Neurotropin and other drugs on changes in brain and plasma catecholamine content in SART-stressed rats. *The Japanese Journal of Pharmacology*, **1987**, 43, 153 | 3 |
| 2 | Changes of total acetylcholine content and the activity of related enzymes in SART (repeated cold)-stressed rat brain and duodenum. *The Japanese Journal of Pharmacology*, **1986**, 40, 174-7 | 20 |
| 1 | Changes of tissue blood flow in mice loaded with SART (repeated cold) stress or restraint and water immersion stress and the effect of administered neurotropin. *The Japanese Journal of Pharmacology*, **1986**, 41, 69-79 | 31 |